West Africa, West Indies, West London: Mechanisms driving heterogeneity in immunity to SARS-CoV-2 variants

Grant number: 226142/Z/22/Z

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2023
    2026
  • Known Financial Commitments (USD)

    $3,678,389.73
  • Funder

    Wellcome Trust
  • Principal Investigator

    Dr. David LV Bauer
  • Research Location

    United Kingdom
  • Lead Research Institution

    The Francis Crick Institute
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen genomics, mutations and adaptations

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older)

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Our proposed WWW Consortium brings together three prospective cohort studies of healthy adults in receipt of COVID-19 vaccination in West Africa, the West Indies, and West London to answer fundamental questions in the immunology of SARS-CoV-2 variants. Given the diverse outcomes of COVID-19 in our respective locations, despite many overlapping characteristics such as shared genetic ancestry and AZD1222 vaccination, we have power to make a significant contribution to understanding the mechanisms underlying the apparent heterogeneity in our cohorts. We have 3 aims: - Harmonise our studies to determine the breadth of immunity to SARS-CoV-2 variants by transferring assay and modelling capacity between sites, while also genotype participants to enable comparison across our mixed-ancestry populations; - Test four hypotheses that may contribute to breadth within and between our cohorts: exposure to prior SARS-CoV-2 variants, to other bat & human coronaviruses, to malaria, and to host immunoreactivity; and - Build models of immune responses to variants that incorporating individual-level data and are applicable in LMIC settings with limited datasets. Together, our work will provide insights into the factors that drive the complex immunology to SARS-CoV-2 variants that can also inform future pandemic response in regions currently underserved by both research and surveillance capacity.

Publicationslinked via Europe PMC

SARS-CoV-2 antibody immunity across three continents: the West Africa, West Indies, West London Consortium

Adults in Ghana generate higher and more durable neutralising antibody titres following primary course COVID-19 vaccination than matched UK adults: The HERITAGE Study.

Chronogram: an R package for data curation and analysis of infection and vaccination cohort studies.